D. Bowen et al., SERUM STEM-CELL FACTOR CONCENTRATION IN PATIENTS WITH MYELODYSPLASTICSYNDROMES, British Journal of Haematology, 85(1), 1993, pp. 63-66
Stem cell factor (SCF) is characterized by its capacity to synergize d
ramatically with other haemopoietic growth factors in in vitro erythro
id, myeloid, and lymphoid progenitor culture systems. We have measured
serum SCF concentrations by enzyme immunoassay in 8 5 patients with m
yelodysplasia (MDS). Serum samples were taken in 1988-89 and in 1991-9
2 and stored at -20-degrees-C. Mean serum SCF concentration in the MDS
patients was 2.81 ng/ml (range 0.6-8.0). This was significantly lower
(P= 0.0001) than the values for 234 normal subjects; mean 3.30 ng/ml
(range 1.3-8.0). No significant relationship between SCF concentration
and peripheral blood counts. bone marrow parameters, red cell transfu
sion status, survival or FAB subtype was found, although a trend of de
creasing SCF concentration from refractory anaemia through sideroblast
ic anaemia and chronic myelomonocytic leukaemia to refractory anaemia
with excess blasts was seen. The reduced SCF serum concentration in so
me patients with myelodysplasia suggests a rationale for therapy with
recombinant SCF in these patients.